Going through cancer isn’t easy for anyone. However, there are groups with clear racial disparities in cancer outcomes. Here is a look at recent developments and collaborations toward eliminating racial disparities so ALL patients have optimal outcomes.

After largely being an unknown risk previously, medical researchers examined MGUS and familial risk in a study. Here’s a look at what was learned from the study, other MGUS incidence information, and MGUS screening recommendations.

Will telemedicine remain as a mainstay for myeloma patients after the pandemic? Learn the prime points from the Myeloma TelemEDucation Empowerment Resource Center.

New research from Heinz Ludwig, MD et al explores the global interrelations between Multiple Myeloma (MM) mortality and countries’ economic resources, patient empowerment, and health access and quality. The study is intended to inform about the associations between these factors, and to improve diagnosis, management, and outcome of patients globally.

Studies centering on vaccinations for myeloma patients have been limited in the past due to their low participation rate in trials coupled with negligent measures of patient outcomes. Learn about compilation of vaccination data.

The Patient Empowerment Network Diverse Partners in Your Myeloma Care program focuses on helping to improve health outcomes for underserved myeloma patients. We’ll take a look at what we know, what we’ve learned, and what help and resources are needed to continue advancing care for BIPOC myeloma patients.